The decrease in pancreatic beta cell functionality and the increase in the insulin sensitivity of T2D patients over the time, eventually gave rise to the imbalance of glycated hemoglobin (A1C) level and antidiabetic treatment gap (Freeman, 2013). The gene discussed is INS; the disease is type 2 diabetes mellitus.